Acquisition of Babich-founded Noria helps Bayer pad radiopharmaceutical pipeline  

A deal unveiled Thursday will help Bayer expand its footprint in alpha-emitting targeted radiopharmaceuticals.

Bayer AG (Xetra:BAYN) announced it will acquire Noria Therapeutics Inc. and its subsidiary PSMA Therapeutics Inc., which have exclusive worldwide rights to targeted radiotherapy and diagnostic technology licensed from Weill Cornell Medicine and Johns Hopkins University, including an actinium 225-labeled, PSMA-targeting small molecule in preclinical development for prostate cancer. Financial details were not disclosed...